Doxa AB (publ) (DOXA.ST)
SEK 0.57
(4.63%)
SEK 0.57
(4.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 269.4 Million SEK | 28.6% |
| 2022 | -45.8 Million SEK | -35.1% |
| 2021 | -33.9 Million SEK | -158.36% |
| 2020 | -13.12 Million SEK | -17.89% |
| 2019 | -11.13 Million SEK | -233.1% |
| 2018 | 8.36 Million SEK | 188.12% |
| 2017 | -9.48 Million SEK | 5.94% |
| 2016 | -10.08 Million SEK | 35.96% |
| 2015 | -15.75 Million SEK | 12.79% |
| 2014 | -18.06 Million SEK | 7.52% |
| 2013 | -19.53 Million SEK | 54.03% |
| 2012 | -42.49 Million SEK | 9.7% |
| 2011 | -47.05 Million SEK | -68.75% |
| 2010 | -27.88 Million SEK | 12.03% |
| 2009 | -31.69 Million SEK | 35.23% |
| 2008 | -48.93 Million SEK | -27.22% |
| 2007 | -38.46 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.9 Million SEK | -17.31% |
| 2024 Q1 | -5.2 Million SEK | -15.56% |
| 2023 Q1 | -10.5 Million SEK | 90.8% |
| 2023 FY | -32.7 Million SEK | 28.6% |
| 2023 Q2 | 209.4 Million SEK | 2094.29% |
| 2023 Q4 | -4.5 Million SEK | -100.81% |
| 2023 Q3 | 554.4 Million SEK | 164.76% |
| 2022 Q1 | -14 Million SEK | -115.5% |
| 2022 FY | -45.8 Million SEK | -35.1% |
| 2022 Q4 | -114.1 Million SEK | -1291.46% |
| 2022 Q3 | -8.2 Million SEK | -109.06% |
| 2022 Q2 | 90.5 Million SEK | 746.43% |
| 2021 FY | -33.9 Million SEK | -158.36% |
| 2021 Q2 | -4.3 Million SEK | -43.33% |
| 2021 Q3 | -6.4 Million SEK | -48.84% |
| 2021 Q4 | 90.3 Million SEK | 1510.94% |
| 2021 Q1 | -3 Million SEK | -19.0% |
| 2020 Q1 | -2.9 Million SEK | -1160.87% |
| 2020 Q3 | -3.9 Million SEK | 0.0% |
| 2020 Q2 | -3.9 Million SEK | -34.48% |
| 2020 Q4 | -2.52 Million SEK | 35.36% |
| 2020 FY | -13.12 Million SEK | -17.89% |
| 2019 Q4 | -230 Thousand SEK | 96.85% |
| 2019 FY | -11.13 Million SEK | -233.1% |
| 2019 Q3 | -7.3 Million SEK | -329.41% |
| 2019 Q2 | -1.7 Million SEK | 10.53% |
| 2019 Q1 | -1.9 Million SEK | 6.77% |
| 2018 FY | 8.36 Million SEK | 188.12% |
| 2018 Q4 | -2.03 Million SEK | -45.57% |
| 2018 Q3 | -1.4 Million SEK | -109.46% |
| 2018 Q1 | -2.9 Million SEK | -392.36% |
| 2018 Q2 | 14.8 Million SEK | 610.34% |
| 2017 FY | -9.48 Million SEK | 5.94% |
| 2017 Q3 | -2.1 Million SEK | 41.67% |
| 2017 Q2 | -3.6 Million SEK | -12.5% |
| 2017 Q1 | -3.2 Million SEK | -444.22% |
| 2017 Q4 | -589 Thousand SEK | 71.95% |
| 2016 Q3 | -2.8 Million SEK | 12.5% |
| 2016 Q2 | -3.2 Million SEK | 8.57% |
| 2016 Q4 | -588 Thousand SEK | 79.0% |
| 2016 FY | -10.08 Million SEK | 35.96% |
| 2016 Q1 | -3.5 Million SEK | 13.62% |
| 2015 FY | -15.75 Million SEK | 12.79% |
| 2015 Q4 | -4.05 Million SEK | -1.3% |
| 2015 Q3 | -4 Million SEK | -8.11% |
| 2015 Q2 | -3.7 Million SEK | 5.13% |
| 2015 Q1 | -3.9 Million SEK | -41.2% |
| 2014 Q3 | -3.3 Million SEK | 44.07% |
| 2014 Q1 | -6.1 Million SEK | -22.88% |
| 2014 Q2 | -5.9 Million SEK | 3.28% |
| 2014 Q4 | -2.76 Million SEK | 16.3% |
| 2014 FY | -18.06 Million SEK | 7.52% |
| 2013 Q4 | -4.96 Million SEK | -21.07% |
| 2013 Q1 | -5.3 Million SEK | -0.4% |
| 2013 FY | -19.53 Million SEK | 54.03% |
| 2013 Q3 | -4.1 Million SEK | 21.15% |
| 2013 Q2 | -5.2 Million SEK | 1.89% |
| 2012 Q4 | -5.27 Million SEK | 0.0% |
| 2012 FY | -42.49 Million SEK | 9.7% |
| 2011 FY | -47.05 Million SEK | -68.75% |
| 2010 FY | -27.88 Million SEK | 12.03% |
| 2009 FY | -31.69 Million SEK | 35.23% |
| 2008 FY | -48.93 Million SEK | -27.22% |
| 2007 FY | -38.46 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AddLife AB (publ) | 585 Million SEK | 53.949% |
| Biotage AB (publ) | 376 Million SEK | 28.351% |
| Bonesupport Holding AB (publ) | 13.93 Million SEK | -1833.955% |
| Elekta AB (publ) | 2.03 Billion SEK | 86.788% |
| iZafe Group AB (publ) | -35.63 Million SEK | 855.998% |
| Ortivus AB (publ) | -17.61 Million SEK | 1629.639% |
| Ortivus AB (publ) | -17.61 Million SEK | 1629.639% |
| Q-linea AB (publ) | -230.58 Million SEK | 216.832% |
| S2Medical AB (publ) | -15.26 Million SEK | 1864.953% |
| Synsam AB (publ) | 696 Million SEK | 61.293% |